Adding Imbruvica to Bendamustine/Rituximab Combination Increases PFS in Phase III Leukemia Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma that received Imbruvica (ibrutinib) in combination with bendamustine and rituximab experienced an 80 percent reduction in the risk of progression or death when compared to patients receiving bendamustine, rituximab and placebo in a phase III trial.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login